INOVIO’s DNA-Encoded Antibody Trial Shows Durable In Vivo Expression
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) announced that results from its Phase 1 proof-of-concept trial evaluating DNA-encoded monoclonal antibodies (DMAbs) for COVID-19 have been published in Nature Medicine. The …
INOVIO’s DNA-Encoded Antibody Trial Shows Durable In Vivo Expression Read More